Biogen, AbbVie yank underperforming MS drug Zinbryta after encephalitis reports

Red Exit sign
Among Zinbryta patients, seven cases of encephalitis and meningoencephalitis have turned up in Germany, with one occurring in Spain, according to the EMA. (Leeroy Agency)

It was a short run, but Biogen and AbbVie’s multiple sclerosis-fighter Zinbryta is coming off markets around the globe.

The pair revealed the decision on Friday, citing safety concerns and adding that “it is in the best interest of patients to voluntarily withdraw worldwide marketing authorizations” for the drug, which won FDA approval in May 2016.

News of the move came the same day as news from the European Medicines Agency that it was “urgently reviewing” Zinbryta following cases of inflammatory brain disorders. Seven cases of encephalitis and meningoencephalitis turned up in Germany, with one occurring in Spain.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Now, the companies will “work collaboratively” with regulators and healthcare providers all over the world as they withdraw the drug. Current Zinbryta patients should speak with their doctors about any questions or concerns, the companies advised.

RELATED: Biogen, AbbVie hit with Zinbryta safety action in EU as MS market heats up

Prior to Friday, regulators had already taken actions around Zinbryta’s liver safety. In the U.S., the product carried a black-box warning—the agency’s most serious—against use in patients with liver problems, along with a risk-management program. And in Europe, regulators put limits on its use and required strict liver monitoring.

With things heating up in the multiple sclerosis space, it wasn’t a good time for a product to be gaining restrictions. Last year saw the entry of Roche’s Ocrevus, an eagerly awaited contender with “blockbuster” written all over it.

“This drug looks increasingly weak,” Bernstein analyst Ronny Gal wrote last summer, citing Zinbryta’s European regulatory woes.

RELATED: Acorda draws buyout interest from neuro-focused Biogen, UCB: report

Meanwhile, MS-focused Biogen may be looking to further diversify through a little dealmaking action. Rumor has it that the big biotech has its eye on Acorda and its forthcoming Parkinson’s medicine, Inbrija.

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.